Á¦¸ñ | Prostate cancer & supplementation with alpha-tocopherol & beta-carotene - ©é Volume 6-2 | ||
---|---|---|---|
ÀÛ¼ºÀÚ | °ü¸®ÀÚ | Á¶È¸¼ö | 2712 |
µî·ÏÀÏ | 2004³â 04¿ù 14ÀÏ | ||
÷ºÎÆÄÀÏ | |||
Volume 6 - 2
In This Issue:
(1) Drug-Nutrient Interactions (2) Antioxidant vitamins & nuclear opacities
Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial
Epidemiologic studies have suggested that vitamin E and beta-carotene may each influence the development of prostate cancer. In the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study, a controlled trial, we studied the effect of alpha-tocopherol (a form of vitamin E) and beta-carotene supplementation, separately or together, on prostate cancer in male smokers.
METHODS:
A total of 29,133 male smokers aged 50-69 years from southwestern Finland were randomly assigned to receive alpha-tocopherol (50 mg), beta-carotene (20 mg), both agents, or placebo daily for 5-8 years (median, 6.1 years). The supplementation effects were estimated by a proportional hazards model, and two-sided P values were calculated.
RESULTS:
We found 246 new cases of and 62 deaths from prostate cancer during the follow-up period. A 32% decrease (95% confidence interval [CI] = -47% to -12%) in the incidence of prostate cancer was observed among the subjects receiving alpha-tocopherol (n = 14564) compared with those not receiving it (n = 14569). The reduction was evident in clinical prostate cancer but not in latent cancer. Mortality from prostate cancer was 41% lower (95% CI = -65% to -1%) among men receiving alpha-tocopherol. Among subjects receiving beta-carotene (n = 14560), prostate cancer incidence was 23% higher (95% CI = -4%-59%) and mortality was 15% higher (95% CI = -30%-89%) compared with those not receiving it (n = 14573). Neither agent had any effect on the time interval between diagnosis and death.
CONCLUSIONS:
Long-term supplementation with alpha-tocopherol substantially reduced prostate cancer incidence and mortality in male smokers. Other controlled trials are required to confirm the findings.
Heinonen OP; Albanes D; Virtamo J; Taylor PR; Huttunen JK; Hartman AM; Haapakoski J; Malila N; Rautalahti M; Ripatti S; Maenpaa H; Teerenhovi L; Koss L; Virolainen M; Edwards BK. Department of Public Health, University of Helsinki, Finland. J Natl Cancer Inst 1998 Mar 18;90(6):440-6. NLM CIT. ID: 98180463. COMMENT: J Natl Cancer Inst 1998 Mar 18;90(6):414-5. J Natl Cancer Inst 1998 Mar 18;90(6):416-7.
|